ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Clinical trial NCT05358808 · TERMINATED
Trial details
- NCT number
- NCT05358808
- Sponsor
- TC Biopharm
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-15
- Primary completion
- 2025-07-30
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.